Matthew R. Durk

Optimized arylomycins are a new class of Gram-negative antibiotics

Peter A. Smith, Michael F. T. Koehler, Hany S. Girgis et al. · Nature · 2018 · 348 citations

Antibiotics, Medicine, New Class +6

1α,25-Dihydroxyvitamin D₃Reduces Cerebral Amyloid-β Accumulation and Improves Cognition in Mouse Models of Alzheimer's Disease

Matthew R. Durk, Kyung Ho Han, Edwin C.Y. Chow et al. · Journal of Neuroscience · 2014 · 150 citations · Full text

Vitamin D Receptor Activation Down-regulates the Small Heterodimer Partner and Increases CYP7A1 to Lower Cholesterol

Edwin C.Y. Chow, Lilia Magomedova, Holly P. Quach et al. · Gastroenterology · 2013 · 85 citations

Metabolic Syndrome, Molecular Pharmacology, Increases Cyp7a1 +13

1α,25-Dihydroxyvitamin D3 Up-Regulates P-Glycoprotein via the Vitamin D Receptor and Not Farnesoid X Receptor in Both fxr(−/−) and fxr(+/+) Mice and Increased Renal and Brain Efflux of Digoxin in Mice In Vivo

Edwin C.Y. Chow, Matthew R. Durk, Carolyn L. Cummins et al. · Journal of Pharmacology and Experimental Therapeutics · 2011 · 80 citations

1α,25‐Dihydroxyvitamin D₃‐liganded vitamin D receptor increases expression and transport activity of P‐glycoprotein in isolated rat brain capillaries and human and rat brain microvessel endothelial cells

Matthew R. Durk, Gary N. Y. Chan, Christopher Campos et al. · Journal of Neurochemistry · 2012 · 74 citations · Full text

Neurochemical Biomarkers, Vdr Ligand, Experimental Pharmacology +16